Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check7 days agoChange DetectedRecruitment status updated to 'No longer looking for participants', indicating enrollment is closed. The history now shows Revision: v3.6.0 and removes the prior Revision: v3.5.5 entry.SummaryDifference0.2%

- Check14 days agoChange DetectedA new revision entry v3.5.5 was added to the study record history, representing an updated version of the record. The previous revision v3.5.4 remains part of the history as the prior version.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedA new revision entry v3.5.4 was added to the study record history, replacing the prior v3.5.3. This reflects an updated version of the record in the history.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page reflects a change in the site/system revision label, indicating an interface or platform version update without modifying the underlying clinical trial record details.SummaryDifference0.1%

- Check78 days agoChange DetectedAdded a Study Status entry and removed an older version date in the record history.SummaryDifference0.2%

- Check92 days agoChange DetectedRevision history updated to include v3.5.0 and remove v3.4.3. This appears to be a UI/backend update with no changes to study data or functionality.SummaryDifference0.1%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.